ATE525073T1 - Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten - Google Patents
Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheitenInfo
- Publication number
- ATE525073T1 ATE525073T1 AT06706432T AT06706432T ATE525073T1 AT E525073 T1 ATE525073 T1 AT E525073T1 AT 06706432 T AT06706432 T AT 06706432T AT 06706432 T AT06706432 T AT 06706432T AT E525073 T1 ATE525073 T1 AT E525073T1
- Authority
- AT
- Austria
- Prior art keywords
- modulation
- tie
- treatment
- kinase activity
- pyrimidylaminobensamides
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 title 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 title 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 abstract 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009109 curative therapy Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64789505P | 2005-01-28 | 2005-01-28 | |
| US66240405P | 2005-03-16 | 2005-03-16 | |
| PCT/EP2006/000686 WO2006079539A2 (en) | 2005-01-28 | 2006-01-26 | Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE525073T1 true ATE525073T1 (de) | 2011-10-15 |
Family
ID=36273382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06706432T ATE525073T1 (de) | 2005-01-28 | 2006-01-26 | Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20080114001A1 (de) |
| EP (1) | EP1843771B1 (de) |
| JP (2) | JP5373288B2 (de) |
| KR (2) | KR20130100371A (de) |
| CN (1) | CN101203224B (de) |
| AT (1) | ATE525073T1 (de) |
| AU (1) | AU2006208638B2 (de) |
| BR (1) | BRPI0606872A2 (de) |
| CA (1) | CA2594687C (de) |
| CY (1) | CY1112568T1 (de) |
| DK (1) | DK1843771T3 (de) |
| ES (1) | ES2373912T3 (de) |
| MX (1) | MX2007009135A (de) |
| PL (1) | PL1843771T3 (de) |
| PT (1) | PT1843771E (de) |
| RU (1) | RU2404776C2 (de) |
| WO (1) | WO2006079539A2 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007065898A1 (en) * | 2005-12-06 | 2007-06-14 | Novartis Ag | Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis |
| US8093259B2 (en) | 2006-05-25 | 2012-01-10 | Novartis Ag | 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma |
| EP1923053A1 (de) * | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmazeutische Zusammensetzung umfassend Nilotinib oder dessen Salz |
| EP2152079A4 (de) | 2007-06-04 | 2011-03-09 | Avila Therapeutics Inc | Heterocyclische verbindungen und ihre verwendung |
| NZ590839A (en) * | 2008-08-13 | 2013-02-22 | Novartis Ag | Treatment of pulmonary arterial hypertension |
| US9207782B2 (en) | 2010-12-16 | 2015-12-08 | Lg Electronics Inc. | Remote controller, remote controlling method and display system having the same |
| WO2020214851A1 (en) * | 2019-04-18 | 2020-10-22 | Aerpio Pharmaceuticals, Inc. | Methods of treating hypertension with activators of tie-2 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728708A (en) * | 1993-10-01 | 1998-03-17 | Novartis Corporation | Pharmacologically active pyridine derivatives and processes for the preparation thereof |
| TW533205B (en) * | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
| MXPA01012442A (es) * | 1999-06-03 | 2004-09-10 | Abbott Gmbh & Co Kg | Compuestos de benzotiazinona y benzoxazinona. |
| US20030199525A1 (en) * | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0222514D0 (en) | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
| WO2004037261A1 (en) * | 2002-10-25 | 2004-05-06 | The Administrators Of The Tulane Educational Fund | Use of n-‘5-‘4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension |
| CA2520255C (en) * | 2003-04-09 | 2014-07-08 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| JP4810427B2 (ja) * | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
| CA2527814A1 (en) * | 2003-06-02 | 2004-12-16 | Abbott Laboratories | Isoindolin-1-one compounds as kinase inhibitors |
| AR045037A1 (es) * | 2003-07-10 | 2005-10-12 | Aventis Pharma Sa | Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. |
| GB0325031D0 (en) * | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
-
2006
- 2006-01-26 BR BRPI0606872-3A patent/BRPI0606872A2/pt not_active IP Right Cessation
- 2006-01-26 EP EP06706432A patent/EP1843771B1/de not_active Expired - Lifetime
- 2006-01-26 ES ES06706432T patent/ES2373912T3/es not_active Expired - Lifetime
- 2006-01-26 RU RU2007132255/15A patent/RU2404776C2/ru not_active IP Right Cessation
- 2006-01-26 AT AT06706432T patent/ATE525073T1/de active
- 2006-01-26 AU AU2006208638A patent/AU2006208638B2/en not_active Ceased
- 2006-01-26 CN CN2006800032580A patent/CN101203224B/zh not_active Expired - Fee Related
- 2006-01-26 JP JP2007552578A patent/JP5373288B2/ja not_active Expired - Fee Related
- 2006-01-26 DK DK06706432.9T patent/DK1843771T3/da active
- 2006-01-26 KR KR1020137019492A patent/KR20130100371A/ko not_active Ceased
- 2006-01-26 KR KR1020077017223A patent/KR101325424B1/ko not_active Expired - Fee Related
- 2006-01-26 MX MX2007009135A patent/MX2007009135A/es active IP Right Grant
- 2006-01-26 WO PCT/EP2006/000686 patent/WO2006079539A2/en not_active Ceased
- 2006-01-26 US US11/815,046 patent/US20080114001A1/en not_active Abandoned
- 2006-01-26 PL PL06706432T patent/PL1843771T3/pl unknown
- 2006-01-26 CA CA2594687A patent/CA2594687C/en not_active Expired - Fee Related
- 2006-01-26 PT PT06706432T patent/PT1843771E/pt unknown
-
2011
- 2011-11-24 CY CY20111101146T patent/CY1112568T1/el unknown
-
2013
- 2013-07-04 JP JP2013140891A patent/JP2013213042A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN101203224B (zh) | 2010-11-03 |
| WO2006079539A2 (en) | 2006-08-03 |
| EP1843771A2 (de) | 2007-10-17 |
| CA2594687C (en) | 2013-10-29 |
| KR20070104567A (ko) | 2007-10-26 |
| PL1843771T3 (pl) | 2012-02-29 |
| PT1843771E (pt) | 2011-12-02 |
| ES2373912T3 (es) | 2012-02-10 |
| JP2008528531A (ja) | 2008-07-31 |
| CN101203224A (zh) | 2008-06-18 |
| AU2006208638B2 (en) | 2010-03-04 |
| KR101325424B1 (ko) | 2013-11-04 |
| RU2404776C2 (ru) | 2010-11-27 |
| WO2006079539A3 (en) | 2007-11-29 |
| DK1843771T3 (da) | 2012-01-16 |
| MX2007009135A (es) | 2007-09-06 |
| CY1112568T1 (el) | 2016-02-10 |
| JP2013213042A (ja) | 2013-10-17 |
| AU2006208638A1 (en) | 2006-08-03 |
| US20080114001A1 (en) | 2008-05-15 |
| CA2594687A1 (en) | 2006-08-03 |
| EP1843771B1 (de) | 2011-09-21 |
| KR20130100371A (ko) | 2013-09-10 |
| RU2007132255A (ru) | 2009-03-10 |
| BRPI0606872A2 (pt) | 2009-07-21 |
| JP5373288B2 (ja) | 2013-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200900779A1 (ru) | Производные дигидропиридина, полезные как ингибиторы протеинкиназы | |
| NO20081454L (no) | Met-kinaseinhibitorer | |
| EA200700851A1 (ru) | Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения | |
| ATE478082T1 (de) | Phosphonate, monophosphonamidate, bisphosphonamidate zur behandlung von virenerkrankungen | |
| ATE438404T1 (de) | Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien | |
| ATE406351T1 (de) | Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| DE602007010303D1 (de) | Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen | |
| ATE476414T1 (de) | Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen | |
| ATE369333T1 (de) | Sulfonamidderivate zur behandlung von krankheiten | |
| ATE375977T1 (de) | Sulfonamidderivate zur behandlung von krankheiten | |
| NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
| CY1112568T1 (el) | Χρηση των πυριμιδυλαμινοβενζαμιδων για τη θεραπεια των νοσων που ανταποκρινονται στην ρυθμιση της δρασης της τιε-2 κινασης | |
| DE602006019468D1 (de) | Diarylharnstoffe zur behandlung von pulmonaler hypertonie | |
| DE602007011398D1 (de) | Trialkylsilylbenzylaminocarboxyindole, indazole und indoline und ihre verwendung zur behandlung von cetp-vermittelten erkrankungen | |
| ATE542536T1 (de) | 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen | |
| DE60328603D1 (de) | Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren | |
| ATE548035T1 (de) | Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat | |
| DE602004022035D1 (de) | Verwendung von pthalide derivativen zur behandlung | |
| DE60219940D1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie | |
| ATE483460T1 (de) | Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut | |
| ATE397000T1 (de) | Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs | |
| DE602005014632D1 (de) | Pyrrol- bzw. imidazolamide zur behandlung von obesitas | |
| EA200600115A1 (ru) | Производные 2-аминобензойной кислоты | |
| DE602005013650D1 (de) | Proteinhydrolysat zur behandlung von müdigkeit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1843771 Country of ref document: EP |